Liraglutide Cost in Washington: Prices, Insurance, and Savings in 2026

What Liraglutide Actually Costs in Washington Right Now

Liraglutide pricing in Washington follows a familiar pattern: a high sticker price that almost nobody pays in full, layered under insurance coverage, discount programs, and compounding alternatives that bring the real out-of-pocket number down significantly. The gap between list price and what patients actually spend is wide enough to change treatment decisions.

Retail Pharmacy Pricing

Novo Nordisk sets the wholesale acquisition cost for branded liraglutide (Saxenda for obesity, Victoza for type 2 diabetes) at $1,349 per month. Washington retail pharmacies in 2026 charge an average cash-pay price of roughly $900 per month, reflecting negotiated discounts and pharmacy benefit manager (PBM) spread. That $900 figure varies by location. Pharmacies in the Seattle metro area tend to price within 5-10% of that average, while rural Eastern Washington pharmacies may charge slightly more due to lower volume 1.

The Compounding Alternative

Licensed 503A compounding pharmacies in Washington can prepare liraglutide for approximately $150 per month. That represents an 83% reduction from the average retail cash price. Compounded liraglutide is not FDA-approved as a finished product, but 503A pharmacies operate legally under Section 503A of the Federal Food, Drug, and Cosmetic Act when dispensing patient-specific prescriptions 2.

How Pricing Compares to Other GLP-1 Options

Liraglutide sits at the lower end of the GLP-1 receptor agonist pricing spectrum in Washington. Semaglutide (Wegovy) lists at over $1,300 per month, and tirzepatide (Zepbound) exceeds $1,000 per month at list price. Liraglutide's once-daily dosing requires more frequent injections than weekly semaglutide, but its broader generic pipeline and compounding availability give it a pricing advantage that matters for uninsured or underinsured patients.

Washington Medicaid Coverage for Liraglutide

Washington Apple Health (the state Medicaid program) covers liraglutide for both chronic weight management and type 2 diabetes. Coverage requires prior authorization (PA), which means the prescribing clinician must document medical necessity before the pharmacy can dispense the medication.

Prior Authorization Requirements

The PA process for liraglutide under Washington Medicaid typically requires documentation of a BMI of 30 or greater (or 27 or greater with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia) for the obesity indication. For type 2 diabetes, the prescriber must show that metformin alone or in combination with other first-line agents has not achieved adequate glycemic control. The Washington Health Care Authority reviews PA requests within 24 hours for urgent cases and up to 5 business days for standard requests 3.

What Approval Looks Like in Practice

Once approved, Washington Medicaid typically covers liraglutide with a $0 to $3 copay for most enrollees. Approval periods run 6 to 12 months before requiring reauthorization. The prescriber may need to document ongoing weight loss (at least 4% of baseline body weight by 16 weeks on the obesity dose) to secure renewal, consistent with the FDA label recommendation to discontinue if that threshold is not met 1.

Managed Medicaid Plans

Most Washington Medicaid managed care organizations (MCOs), including Molina Healthcare of Washington, Community Health Plan of Washington, and Coordinated Care, follow the same PA criteria. Some MCOs may have slightly different step-therapy requirements, so patients should confirm with their specific plan.

Is Compounded Liraglutide Legal in Washington?

Yes. Compounded liraglutide is legal in Washington when dispensed by a licensed 503A pharmacy with a valid patient-specific prescription. Washington state law aligns with federal 503A regulations, permitting compounding pharmacies to prepare medications that are copies of commercially available drugs under certain conditions, including when the prescriber documents a clinical difference (such as a different concentration, preservative-free formulation, or specific dose form) 2.

503A vs. 503B: What the Distinction Means for Patients

A 503A pharmacy compounds patient-specific prescriptions. The pharmacist prepares the medication after receiving a prescription for an individual patient. A 503B outsourcing facility operates under FDA oversight and can compound without patient-specific prescriptions, distributing to healthcare facilities in bulk. Both pathways are active in Washington. For individual patients seeking compounded liraglutide, the 503A route is the standard path.

Quality Considerations

The Washington State Pharmacy Quality Assurance Commission inspects and licenses compounding pharmacies in the state. Patients should verify that their compounding pharmacy holds a current Washington license and ask about third-party potency and sterility testing. The FDA has issued warning letters to compounding pharmacies nationally for GLP-1 receptor agonist preparations that failed potency testing, so verification is not a formality 2.

Insurance Coverage Beyond Medicaid

Commercial insurance coverage for liraglutide in Washington varies by plan, employer, and indication. The diabetes indication (Victoza, 1.8 mg) carries broader formulary coverage than the obesity indication (Saxenda, 3.0 mg) across most Washington insurers.

Major Washington Insurers

Premera Blue Cross and Regence BlueShield, the two largest commercial insurers in Washington, both include liraglutide on their formularies for type 2 diabetes. Coverage for the obesity indication is less consistent. Premera added obesity-indication GLP-1 coverage for large-group employer plans in 2025, but individual market plans may still exclude it. Regence covers Saxenda for weight management only on select employer-sponsored plans with a PA requirement 4.

Kaiser Permanente Washington covers liraglutide for type 2 diabetes on its standard formulary. For obesity, Kaiser's coverage depends on the specific plan purchased by the employer.

Self-Insured Employer Plans

A growing number of Washington employers (Amazon, Microsoft, Costco, and Starbucks among them) self-insure their health plans. Self-insured plans are governed by federal ERISA law, not Washington state insurance mandates. Coverage decisions rest entirely with the employer and their PBM. Patients on self-insured plans should check their specific plan documents or call the number on their insurance card.

TRICARE and Federal Employees

TRICARE covers liraglutide for type 2 diabetes through its formulary. The obesity indication requires PA and step therapy (documentation of failed lifestyle intervention). Federal Employees Health Benefits (FEHB) plans in Washington vary by carrier, but Blue Cross Blue Shield FEP covers liraglutide for diabetes with preferred-tier copays.

The SCALE Trial: Why Liraglutide Works at 3.0 mg

The clinical evidence supporting liraglutide for weight management comes primarily from the SCALE (Satiety and Clinical Adiposity, Liraglutide Evidence) program. The largest trial in that program, SCALE Obesity and Prediabetes, randomized 3,731 adults without diabetes to liraglutide 3.0 mg daily or placebo, both combined with lifestyle counseling 4.

Primary Outcomes

At 56 weeks, liraglutide 3.0 mg produced a mean weight loss of 8.0% of body weight compared with 2.6% for placebo. 63.2% of liraglutide-treated participants lost at least 5% of their body weight, versus 27.1% in the placebo group. One-third of participants on liraglutide achieved 10% or greater weight loss 4.

Prediabetes Reversal

Among participants with prediabetes at baseline (61% of the study population), liraglutide reduced the risk of developing type 2 diabetes by 79% over the 56-week treatment period. The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity cites this finding as supporting liraglutide use in patients with prediabetes and overweight or obesity 5.

Dr. Xavier Pi-Sunyer, the lead investigator of SCALE Obesity and Prediabetes, stated: "The magnitude of weight loss with liraglutide 3.0 mg, combined with the metabolic improvements we observed, supports its role as a treatment option for patients who have not achieved adequate weight loss through lifestyle modification alone."

How Liraglutide Compares to Semaglutide

Semaglutide 2.4 mg (Wegovy) produced 14.9% mean body weight loss at 68 weeks in the STEP-1 trial (N=1,961), roughly double the weight loss seen with liraglutide 3.0 mg 6. That difference matters clinically. But liraglutide's lower cost through compounding, its longer post-market safety record (FDA-approved since 2014 for obesity, 2010 for diabetes), and its daily dosing flexibility make it a reasonable first-line GLP-1 option for patients in Washington who face cost barriers to semaglutide.

Cheapest Ways to Get Liraglutide in Washington

The actual price a patient pays depends on their coverage situation. Here is a ranked breakdown from lowest to highest typical monthly cost.

Compounded Liraglutide via 503A Pharmacy

Approximately $150 per month. This is the lowest-cost option for uninsured patients or those whose plans do not cover GLP-1 medications for obesity. Requires a prescription. Available via telehealth in Washington 2.

Washington Medicaid with Prior Authorization

$0 to $3 per month copay for approved patients. Eligibility depends on income (up to 138% of the federal poverty level for adults under the ACA Medicaid expansion) 3.

Novo Nordisk Savings Card

Commercially insured patients may pay as little as $25 per month for up to 12 months using the Novo Nordisk co-pay savings card. The card covers the difference between the patient's copay and $25, up to a maximum annual benefit. This does not apply to government-insured patients (Medicaid, Medicare, TRICARE) 1.

Commercial Insurance with Formulary Coverage

Typical copay of $30 to $150 per month for patients with commercial plans that cover liraglutide. Specialty-tier placement increases cost-sharing on some plans.

Cash Pay at Retail Pharmacy

Average of $900 per month in Washington. This is the option of last resort for patients who cannot access any of the above pathways.

Telehealth Prescribing in Washington

Washington state permits telehealth prescribing of liraglutide without restrictions. The Washington Medical Commission allows prescribers to establish a patient-provider relationship via audio-video telehealth and prescribe controlled and non-controlled medications. Liraglutide is not a controlled substance, so it faces no additional telehealth prescribing barriers 7.

How Telehealth Changes Access

Telehealth access matters disproportionately in Washington because of the state's geography. Eastern Washington, the Olympic Peninsula, and rural areas along the Cascade Range have limited endocrinology and obesity medicine specialist coverage. Telehealth allows patients in these regions to access prescribers who can evaluate, prescribe, and manage liraglutide therapy without requiring a multi-hour drive to Seattle, Spokane, or Tacoma.

What a Typical Telehealth Visit Looks Like

A patient contacts a licensed telehealth provider (either a Washington-licensed physician, nurse practitioner, or physician assistant). The provider reviews the patient's medical history, BMI, comorbidities, and prior weight-loss attempts via video visit. If liraglutide is appropriate, the provider writes a prescription that can be filled at a retail pharmacy or a 503A compounding pharmacy. Follow-up visits at 4-week and 16-week marks assess tolerability and weight-loss response.

Dosing and Titration Schedule

Liraglutide for weight management (Saxenda) follows a 5-week titration schedule to reduce gastrointestinal side effects 1.

Standard Titration

• Week 1: 0.6 mg once daily
• Week 2: 1.2 mg once daily
• Week 3: 1.8 mg once daily
• Week 4: 2.4 mg once daily
• Week 5 and beyond: 3.0 mg once daily (maintenance dose)

The Endocrine Society recommends evaluating response at 16 weeks on the maintenance dose. If the patient has not lost at least 4% of baseline body weight, discontinuation should be considered because continued treatment is unlikely to produce a clinically meaningful response 5.

Common Side Effects During Titration

Nausea affects approximately 39% of patients during the titration phase but typically resolves or diminishes by week 8. Constipation (19%), diarrhea (21%), and injection-site reactions (13.9%) are the other most frequently reported adverse events in the SCALE program 4.

The 2024 American Gastroenterological Association guideline on pharmacological interventions for obesity states: "GLP-1 receptor agonists should be initiated at low doses with gradual titration to minimize gastrointestinal adverse effects, and patients should be counseled that nausea is typically transient" 7.

Who Should Not Take Liraglutide

Liraglutide carries a boxed warning for thyroid C-cell tumors based on rodent studies. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). In the SCALE trials, no cases of MTC were reported in liraglutide-treated patients, but the theoretical risk requires screening and informed consent 1.

Other Contraindications

Patients with a history of pancreatitis should use liraglutide with caution. Liraglutide should not be combined with other GLP-1 receptor agonists or with insulin for the obesity indication. Pregnant patients should not use liraglutide; the FDA label recommends discontinuing at least 2 months before a planned pregnancy due to the drug's long washout period.